Background: The European Academy of Allergy and Clinical Immunology (EAACI) is
We have recently completed systematic reviews investigating the role of AIT in the management of allergic rhinitis, asthma, food allergy and venom allergy focusing on the effectiveness, safety and cost-effectiveness of AIT. [1] [2] [3] [4] During the course of undertaking these reviews, we identified a number of health economic evaluations, which we considered it prudent to synthesize with a view to drawing overarching insights into the state of this evidence base and in order to guide future evaluations.
Our specific aims were to:
• Synthesize data on the cost-effectiveness of AIT for the clinical management of allergic rhinitis, allergic asthma, IgE-mediated food allergy and venom allergy from the perspective of health payers; and
• Identify research gaps in relation to the cost-effectiveness of AIT for these conditions.
| ME TH ODS
A detailed outline of the methods has previously been published in the protocols and papers of each individual review. [1] [2] [3] [4] [5] [6] [7] [8] We therefore confine ourselves to a synopsis of the methods employed. The review has been conceptualised in figure 1.
| Search strategies
Highly sensitive search strategies were developed, and validated study design filters were applied to retrieve articles pertaining to the use of AIT for allergic rhinitis, asthma, food allergy and venom allergy from electronic bibliographic databases. The search strategies were developed on OVID MEDLINE and then adapted for the other databases. [1] [2] [3] [4] In all cases, the databases were searched from inception to 31 October 2015. Additional papers were located through searching the references cited by the identified studies, and unpublished work and research in progress were identified through discussion with experts in the field. There were no language restrictions employed.
| Study selection
All references were uploaded into the systematic review software DistillerSR, and duplicate records were removed. Studies were independently checked by two reviewers (SD, MA, AaS) against the inclusion criteria detailed in the reviews. [1] [2] [3] [4] Any discrepancies were resolved through discussion and, when necessary, a third reviewer was consulted (AS).
| Quality assessment
Quality assessments were independently carried out on each study by two reviewers (MA and SD). The Critical Appraisal Skills Programme (CASP) Economic Evaluation Checklist for health economic studies was used for this purpose. 9 Any discrepancies were resolved by discussion or arbitration by a third reviewer (AS).
| Data extraction, analysis and synthesis
A data extraction sheet was developed to capture the pertinent features of the cost-effectiveness analysis based on the Drummond checklist and the National Institute for Health and Clinical Excellence (NICE) reference case for economic evaluations. 10, 11 Data were independently extracted onto a customized data extraction sheet developed for the purposes of these reviews by two reviewers (MA, AaS or SD), and any discrepancies were resolved by discussion or arbitration by a third reviewer (AS). Where studies reported results from multiple perspectives, results from the health system perspective were presented, and where there were multiple outcome measures including quality-adjusted life years (QALYs), the focus of the review was to present results in terms of QALYs.
Costs were translated to 2014/15 GBP = Great Britain Pound prices using National Health Service Personal Social Services
Research Unit (NHS PSSRU) inflation indices 12 and standard exchange rates to aid the comparability of the studies.
A detailed descriptive report was produced on each study to summarize the literature. This data extraction process was used to assess the methodological features of the applied economic evaluations and highlight key methodological gaps in the studies from a health economics perspective. The summary tables are reproduced in the results section of this article, with full data extraction forms available in Appendix S1.
| Registration and reporting
The underpinning reviews have been registered with the International Prospective Register of Systematic Reviews (PROSPERO):
Allergic Rhinitis: CRD42016035373; Allergic Asthma:
CRD42016035372; Venom: CRD42016035374; Food Allergy:
CRD42016039384. The Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) checklist was used to guide the reporting of the systematic review (Appendix S2).
3 | RESULTS
| Overall description
Our searches yielded 21 studies assessing the cost-effectiveness of allergic rhinitis, asthma and venom allergy that met our inclusion criteria (see Table 1 and Appendix S1). Two of these studies are included separately in both asthma and rhinitis analyses. Nineteen studies focussed on allergic rhinitis, 13-31 three on asthma 13, 14, 32 and one on venom allergy. 33 No studies were identified investigating the cost-effectiveness of food allergy. We identified studies looking at both sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT), and which included both children and adults.
| Quality assessment
The overall quality of the studies was low. Of the 19 allergic rhinitis studies, nine were assessed to be of low quality, 13, [16] [17] [18] [19] 22, 24, 28, 29 six medium 15, 20, 21, 23, 25, 30 and four high quality. 14, 26, 27, 30 Of the three asthma studies, two were of a low quality 13, 32 and one high quality. 14 The one included venom allergy study was assessed to be of medium quality. 33 The quality of the studies is summarized in Table 2a -e.
| Summary of evidence
We begin by briefly summarizing the data in relation to each condition and then synthesize findings across this body of evidence in order to highlight gaps and provide insights to inform the planning of future studies.
| Allergic rhinitis
Of the 19 allergic rhinitis studies, two focussed on patients who all had both allergic rhinitis and allergic asthma 13, 14 and the remaining 17 focussed on patients who had allergic rhinitis (some of whom also had asthma, but it was difficult to know how many because of lack of clarity in the descriptions of studies). Three of these studies reported results from a societal perspective 18, 21, 23 with the remaining 16 reporting information from a health system perspective.
Studies were based in a range of countries: Germany (N = . Three studies reported including participants from more than one country. 15, 18, 20 Seven of the studies reported results against disease-specific outcome measures whilst the remaining twelve reported results based on QALYs. A detailed summary of each study can be found in Table 1 and Appendix S1.
Thirteen of the studies [13] [14] [15] [18] [19] [20] [21] [24] [25] [26] [27] 30, 31 were based on randomized controlled trial (RCT) data or meta-analyses of RCT data including two model-based evaluations. 26, 30 The remaining studies were based on a mixture of questionnaires, observational data and expert opinion. None of the studies based on nonrandom data attempted to control for selection bias. None of the RCT-based studies described the amount of missing data in the study or explained how if at all any missing data were imputed for in the analyses.
Study time horizons ranged between 1 and 15 years with the longer time horizon studies typically based on much shorter followup trial data (typically 1 year) and assuming constant continued treatment effects after AIT was discontinued.
Nine of the studies 13 There were seven studies based on RCT data conducted from a health system perspective and using QALYs as their outcome measure. Two high-quality studies were based in the UK. The first found that in patients with both rhinitis and asthma, the incremental cost- In general, the studies find that AIT and where defined both SLIT and SCIT were more effective than standard care, but also more expensive. The studies that compared SLIT with SCIT gave mixed results not allowing us to conclude that either treatment is necessarily more effective or more costly than the other from a health system perspective. The studies comparing SLIT (Grazax) and SLIT (Oralair) suggested SLIT (Oralair) is both more effective and cheaper than SLIT (Grazax).
19,31
The seven RCT studies compared, disregarding the caveats about generalizability, suggested that SLIT and SCIT treatment would be considered cost-effective in this patient population in UK at the standard NICE cost-effectiveness threshold of £20 000 per QALY.
However, the quality of the studies and the general lack of attention to characterizing uncertainty and handling missing data should be taken into account when interpreting these results.
| Asthma
Three studies were deemed suitable for use in the review of AIT to treat patients with allergic asthma. Data extraction of these studies is summarized in Table 1 .
Of the three health economic studies included, only one lowquality study focussed on patients with allergic asthma without reported rhinitis. 32 This was carried out in Germany and compared SCIT with standard care based on a small-scale RCT (N = 65) with three years of follow-up data. The study used a disease-specific outcome measure (mean morning peak flow) with no attempt to convert it to a general quality-of-life measure such as QALYs making it impossible to assess the cost-effectiveness of the treatment. The study found that over the 3 years, SCIT was more expensive than standard care and performed better than standard care on the disease-specific outcome measure.
The remaining two studies looked at people with both allergic rhinitis and asthma. The first of these compared SLIT with standard The final study, also in patients with rhinitis and asthma, based on an RCT (N = 70) with 5 years of follow-up conducted in Italy compared SLIT with standard care and found that patients on SLIT cost less and suffered less symptoms than those on standard care. 13 Methods of the study were not presented in enough detail to understand the analysis that had been performed and there was no attempt to convert the symptom score reported in the study to a general quality-of-life scale making it impossible to undertake a formal assessment of cost-effectiveness.
From the very limited set of studies found, all of which had significant methodological limitations, we can conclude that there is a suggestion that SLIT, when used in patients with both allergic asthma and allergic rhinitis, may be cost-effective from an English NHS perspective with an ICER of £10 726 per QALY, well below the stated NICE threshold on £20 000 per QALY.
| Venom allergy
Only one study of moderate quality was found that looked at the economic evaluation of AIT for venom. 33 This was a modelling study looking at the cost-effectiveness of AIT for the treatment of bee and wasp venom allergy ( Table 1 HDA + AAI and avoidance advice only, respectively), but more effective than other treatment options with the potential for cost saving in patients likely to be stung more than five times a year (eg bee keepers).
This study, despite the fact that it was based largely on expert opinion and plausible assumptions, suggested that AIT for bee and wasp venom allergy was only likely to be cost-effective from an English NHS perspective for very high-risk groups likely to be exposed to multiple exposures to venom per year. The modelling study suggested plausible ranges of exposure to such events to qualify a patient as a member of a high-risk group and explored a wide range of sensitivity
and scenario analyses to demonstrate the robustness of its findings.
| Food allergy
We found no studies that met our inclusion criteria that looked at the cost-effectiveness of AIT for food allergy. Studies are needed in this area to provide information on this rapidly expanding treatment area.
| Gaps in the literature
There is significant scope for future well-designed studies looking at identified looking at AIT for the treatment of allergic rhinitis suggest that SLIT and SCIT treatment would be considered cost-effective for these conditions in England at the standard NICE cost-effectiveness threshold of £20 000 per QALY. However, the quality of the studies and the general lack of attention to characterizing uncertainty and handling missing data should be taken into account when interpreting these results.
| Strengths and limitations
Our search strategies were robust and comprehensive filtering the vast literature pertaining to the subject. Furthermore, we actively sought expert opinions to add to the literature in case we had missed studies. There is, however, always the possibility as with all such overviews that some studies may not have been identified or have slipped through our search processes. 
| Interpretation in the light of the previous literature
This is, as far as we are aware, the first economic overview of AIT that has been conducted in relation to the conditions under study.
| Implications for policy, practice and research
The findings from this overview will be considered together with the related evidence on the effectiveness and safety of AIT in drawing up guidelines and developing recommendations for practice. The findings from this analysis will be particularly helpful in relation to countries such as the UK and the Netherlands that have an explicit focus on health economic evaluations when deciding whether to promote the use of interventions throughout their health systems.
That said, with increasing pressure on health budgets globally the findings from this study are also likely to be of wider interest.
This work has also highlighted the need for investigators routinely to consider including formal cost-effectiveness analyses in their research plans and ensuring that these studies are undertaken to international standards. Consideration also needs to be given to undertaking health economic analyses from societal/patient perspectives as the condition can result in a significant personal societal/ economic burden.
| CONCLUSIONS
Overall, the evidence to support the cost-effectiveness of AIT is limited and of a low methodological quality but appears to suggest that from an English NHS perspective AIT is cost-effective for allergic rhinitis, asthma and venom allergy in very high-risk subgroups. No studies were identified assessing the cost-effectiveness of AIT for treating people with food allergy. There is much scope for further high-quality studies addressing the methodological gaps identified in this review assessing the cost-effectiveness of AIT against various allergic conditions.
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